Table 5.
Neoadjuvant endocrine therapy efficacy according to genomic score.
| Study | N = | Clinical Response Rate | Breast-Conserving Surgery Rate | Pathological Response | Relapse-Free Survival |
|---|---|---|---|---|---|
| OncotypeDx | |||||
| TransNEOS trial (71) | 295 | Low RS: 54% Inter RS: 42% High RS: 22% |
Low RS: 79% High RS: 60% |
NR | NR |
| JFMC34-0601 Ueno et al. (69)(73) |
64 and 59 | Low RS: 59% High RS: 20% |
Low RS: 91% Inter RS: 77% High RS: 47% |
NR | Low RS: 90% Inter RS: 75% High RS: 50% Combined RS (pre/post NET): no recurrence in the low RS group. |
| Akashi-Tanaka et al. (70) | 43 | Low RS: 64% Inter RS: 31% High RS: 31% |
NR | NR | Low RS: 100% Inter RS: 84% High RS: 73% |
| Bear (72) Low RS < 11 Inter RS 11-25 |
30 | Low RS 83% Inter RS: 50% |
Low RS 75% Inter RS: 72% |
pCR Low RS: 8.3% Inter RS: 6% |
NR |
| Endopredict | |||||
| ABCSG-34 trial(47) | 83 | NR | NR | RCB0-I Low MS 27% High MS 8% |
NR |
NR: not reported; Inter: intermediate; pCR: pathological complete response; MS: 12-gene molecular score. If not specified, low RS < 18 and high RS ≥ 31.